Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Tarlatamab |
Trade Name | Imdelltra |
Synonyms | AMG 757|AMG757|AMG-757|tarlatamab-dlle |
Drug Descriptions |
Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov). |
DrugClasses | CD3 Antibody 99 DLL3 Antibody 6 |
CAS Registry Number | 2307488-83-9 |
NCIT ID | C147027 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AMG 404 + Tarlatamab | AMG 404 Tarlatamab | 0 | 1 |
Atezolizumab + Carboplatin + Etoposide + Tarlatamab | Atezolizumab Carboplatin Etoposide Tarlatamab | 0 | 1 |
Atezolizumab + Tarlatamab | Atezolizumab Tarlatamab | 0 | 1 |
Durvalumab + Tarlatamab | Durvalumab Tarlatamab | 0 | 1 |
Tarlatamab | Tarlatamab | 0 | 6 |